Fort Myers, Fla., Dec. 22, 2021 – Florida Cancer Specialists & Research Institute, LLC (FCS) medical oncologist Gail Lynn Shaw Wright, MD, FACP, FCCP is co-author of a Phase II study that examined the efficacy of administering Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer. Results from the randomized patient study were published in Clinical Cancer Research.
It is estimated that approximately 15 – 20 percent of the nearly 300,000 new cases of invasive breast cancer diagnosed annually in the United States are classified as triple-negative, which is considered an aggressive cancer with a poorer prognosis than other types of breast cancer and more likely to return after treatment. Trilaciclib is a medication used to help protect bone marrow cells from damage during chemotherapy, making it a safer and more tolerable treatment for patients with triple-negative breast cancer.
The study’s analysis indicates that T-cell activation was enhanced in patients receiving Trilaciclib. Dr. Wright and her fellow co-authors concluded: “Administering Trilaciclib prior to GCb enhanced antitumor efficacy, with significant improvements in OS (overall survival). Efficacy outcomes in immunologic subgroups and enhancements in T-cell activation suggest these improvements may be mediated via immunologic mechanisms.”
To read the complete research article, visit: https://clincancerres.aacrjournals.org/content/early/2021/12/06/1078-0432.CCR-21-2272.abstract